광견병 백신 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2026-2035년)

The Global Rabies Vaccine Market was valued at USD 1.2 billion in 2025 and is estimated to grow at a CAGR of 4.5% to reach USD 1.9 billion by 2035.

Market expansion is strongly influenced by increasing awareness regarding rabies prevention, a rising incidence of animal bite cases, and the growing reliance on post-exposure prophylaxis (PEP). Government-led immunization initiatives across developing regions are also playing a critical role in accelerating vaccine adoption. At the same time, global efforts aimed at eliminating rabies-related mortality and improving vaccine accessibility in low- and middle-income countries are further strengthening demand.

Rabies continues to represent a serious public health challenge, especially across Asia and Africa, where exposure risks remain comparatively high. Rabies vaccines are biological preparations developed to activate immunity against the rabies virus, a disease that is almost always fatal once clinical symptoms develop. These vaccines are administered as pre-exposure prophylaxis (PrEP) for high-risk groups such as laboratory professionals, veterinarians, and travelers, as well as post-exposure prophylaxis following animal bites or scratches. The market has shown steady growth due to expanding government-backed vaccination programs, increasing investment in animal rabies control, and rising healthcare expenditure in endemic regions. Countries such as India and China, along with several African nations, are actively scaling up prevention programs through mass dog vaccination drives and improved human vaccine access.

The Baby Hamster Kidney (BHK) segment generated USD 492 million in 2025. This segment is widely utilized in rabies vaccine production because it supports efficient large-scale viral cultivation in controlled environments. BHK cell platforms are extensively used in manufacturing inactivated rabies vaccines due to their strong viral yield, rapid growth characteristics, and ability to facilitate efficient virus propagation during bioprocessing. The increasing shift toward cell culture-based vaccine production, replacing older nerve tissue-derived methods, has further reinforced the adoption of BHK-based technologies in rabies vaccine manufacturing.

The human segment accounted for 68.8% share in 2025. It remains the dominant category due to the high global incidence of human rabies exposure and the increasing need for post-exposure prophylaxis following animal bites. Growth in this segment is supported by rising public awareness of immediate treatment requirements, expanding immunization programs backed by governments, and improved availability of advanced cell culture-based vaccines. Additionally, increasing healthcare expenditure, broader vaccine accessibility in endemic regions, and sustained public health initiatives aimed at eliminating human rabies deaths are further supporting segment expansion.

North America Rabies Vaccine Market held a 39.3% share in 2025. The region's dominance is supported by advanced healthcare infrastructure, strong awareness of rabies prevention, and broad access to post-exposure prophylaxis services, particularly in the United States.

A few of the prominent players operating in the global rabies vaccine industry include Sanofi, Merck & Co., Zoetis, Boehringer Ingelheim, Bavarian Nordic, Elanco Animal Health, Virbac, AIM Vaccine, Bharat Biotech, Biogenesis Bago, Cadila Pharmaceuticals, Chengdu Institute of Biological Products, Liaoning Cheng Da Co., Ltd., Indian Immunologicals Ltd., and Zydus Lifesciences. Companies in the rabies vaccine market are focusing on strengthening production scalability through advanced cell culture technologies and continuous upgrades in biomanufacturing capabilities. Strategic collaborations with public health organizations and governments are helping expand vaccination coverage in endemic regions. Manufacturers are also investing in research to improve vaccine safety, efficacy, and storage stability. Expansion of distribution networks, particularly in rural and underserved areas, is improving accessibility. In addition, firms are increasing investments in awareness campaigns and veterinary vaccination programs to reduce transmission at the source. Portfolio diversification, regulatory approvals in emerging markets, and capacity expansion through facility upgrades are further supporting long-term market positioning and competitive advantage.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Type trends
  • 2.2.4 Application trends
  • 2.2.5 Distribution channel trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of animal bite cases
    • 3.2.1.2 Government-led rabies elimination programs
    • 3.2.1.3 Growing awareness regarding preventive vaccination
    • 3.2.1.4 Expansion of healthcare access in emerging economies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Limited access in low-income regions
    • 3.2.2.2 High cost of post-exposure treatment
    • 3.2.2.3 Underreporting of rabies cases
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of "Zero by 30" global initiative
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 MEA
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies (Driven by Primary Research)
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Pricing analysis (Driven by Primary Research)
  • 3.8.1 Historical price trend analysis
  • 3.8.2 Pricing strategy, by product type
• 3.9 Pipeline analysis and clinical trial landscape
• 3.10 Future market trends (Driven by primary research)
• 3.11 Investment & funding analysis
• 3.12 Impact of AI and Generative AI on the market

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis (Driven by primary research)
  • 4.3.1 Global
  • 4.3.2 North America
  • 4.3.3 Europe
  • 4.3.4 Asia Pacific
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product Type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Baby Hamster Kidney (BHK)
• 5.3 Purified chick embryo cell rabies vaccine
• 5.4 Vero cell rabies vaccine
• 5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Human
• 6.3 Veterinary

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pre exposure prophylaxis
• 7.3 Post exposure prophylaxis

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AIM Vaccine
• 10.2 Bharat Biotech
• 10.3 Boehringer Ingelheim
• 10.4 Bavarian Nordic
• 10.5 BiogenesisBago
• 10.6 Chengdu Institute of Biological Products
• 10.7 Cadila Pharmaceuticals
• 10.8 Elanco Animal Health
• 10.9 Indian Immunologicals Ltd.
• 10.10 Liaoning Cheng Da Co., Ltd.
• 10.11 Merck & Co.
• 10.12 Sanofi
• 10.13 Virbac
• 10.14 Zoetis
• 10.15 Zydus Lifesciences